{"id":2051,"date":"2026-03-17T13:23:00","date_gmt":"2026-03-17T17:23:00","guid":{"rendered":"https:\/\/sites.nd.edu\/pdnano\/?p=2051"},"modified":"2026-05-08T01:26:36","modified_gmt":"2026-05-08T05:26:36","slug":"its-official-u-s-patent-no-12576160-issued-for-our-bispecific-bridge-nanoparticle-technology","status":"publish","type":"post","link":"https:\/\/sites.nd.edu\/pdnano\/?p=2051","title":{"rendered":"It’s Official: U.S. Patent No. 12,576,160 Issued for Our Bispecific Bridge Nanoparticle Technology"},"content":{"rendered":"\n

I am delighted to share that on March 17, 2026<\/strong>, the United States Patent and Trademark Office officially issued U.S. Patent No. 12,576,160<\/strong> for our technology, “Bispecific bridge nanoparticles for efficient targeting of cancer cells using immunotherapy (universal CAR-T cells) or chemotherapeutic”<\/em> (Notre Dame docket P21-043-US01<\/strong>). This is the same invention that received its Notice of Allowance back in January, and I am thrilled to see it cross the finish line ahead of schedule.<\/p>\n\n\n\n

From Allowance to Issued Patent<\/strong> Earlier this year, we announced the Notice of Allowance<\/a> for Application US 18\/547,664. With the patent now formally issued, our team holds enforceable rights protecting the bispecific bridge nanoparticle approach for:<\/p>\n\n\n\n

    \n
  1. Universal CAR-T Cell Therapy:<\/strong> Enabling engineered T-cells to recognize and engage a broad range of cancer cell types through the nanoparticle bridge.<\/li>\n\n\n\n
  2. Targeted Chemotherapy:<\/strong> Delivering cytotoxic payloads with greater precision to tumor cells while sparing healthy tissue.<\/li>\n<\/ol>\n\n\n\n

    The patent will remain in force until March 13, 2043<\/strong>, with maintenance fees already docketed by the University.<\/p>\n\n\n\n

    A Team Effort<\/strong> Issuance of a U.S. patent is never a one-person achievement. My sincere thanks to Carrie Jennings<\/strong> and the team at the University of Notre Dame IDEA Center<\/strong> for shepherding the application through to grant, and to every student and collaborator who contributed to the underlying science. This milestone is as much theirs as it is mine.<\/p>\n\n\n\n

    What This Unlocks<\/strong> With the patent issued, we can move forward more confidently on conversations around licensing, sponsored research, and translational partnerships. The bispecific bridge platform was conceived to address two of the hardest problems in cancer therapy \u2014 universal targeting for cell therapies and improved selectivity for chemotherapeutics \u2014 and we are excited to begin the next phase of moving this technology toward clinical impact.<\/p>\n\n\n\n

    More to come.<\/p>\n\n\n\n

    Science #CancerCure #NotreDame #Biotech #Patented #CART #Nanomedicine<\/p>\n","protected":false},"excerpt":{"rendered":"

    I am delighted to share that on March 17, 2026, the United States Patent and Trademark Office officially issued U.S. Patent No. 12,576,160 for our technology, “Bispecific bridge nanoparticles for efficient targeting of cancer cells using immunotherapy (universal CAR-T cells) or chemotherapeutic” (Notre Dame docket P21-043-US01). This is the same invention that received its Notice … <\/p>\n

    Continue reading »<\/a><\/p>\n","protected":false},"author":2672,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[313553,405092,405119,405107,405111,405118],"class_list":["post-2051","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-nallathambylab","tag-berthiaume-institute-for-precision-health","tag-cancercure","tag-nanomedicine","tag-notredameresearch","tag-patent"],"yoast_head":"\nIt's Official: U.S. Patent No. 12,576,160 Issued for Our Bispecific Bridge Nanoparticle Technology - Nallathamby Laboratory<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/sites.nd.edu\/pdnano\/?p=2051\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"It's Official: U.S. Patent No. 12,576,160 Issued for Our Bispecific Bridge Nanoparticle Technology - Nallathamby Laboratory\" \/>\n<meta property=\"og:description\" content=\"I am delighted to share that on March 17, 2026, the United States Patent and Trademark Office officially issued U.S. Patent No. 12,576,160 for our technology, “Bispecific bridge nanoparticles for efficient targeting of cancer cells using immunotherapy (universal CAR-T cells) or chemotherapeutic” (Notre Dame docket P21-043-US01). This is the same invention that received its Notice … Continue reading »\" \/>\n<meta property=\"og:url\" content=\"https:\/\/sites.nd.edu\/pdnano\/?p=2051\" \/>\n<meta property=\"og:site_name\" content=\"Nallathamby Laboratory\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/prakashdn\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-17T17:23:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-08T05:26:36+00:00\" \/>\n<meta name=\"author\" content=\"Prakash\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@prakashdn\" \/>\n<meta name=\"twitter:site\" content=\"@prakashdn\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Prakash\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/?p=2051#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/?p=2051\"},\"author\":{\"name\":\"Prakash\",\"@id\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/#\\\/schema\\\/person\\\/3bec2d9fbd957b23abd53a0a5445b4f0\"},\"headline\":\"It’s Official: U.S. Patent No. 12,576,160 Issued for Our Bispecific Bridge Nanoparticle Technology\",\"datePublished\":\"2026-03-17T17:23:00+00:00\",\"dateModified\":\"2026-05-08T05:26:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/?p=2051\"},\"wordCount\":310,\"keywords\":[\"#nallathambylab\",\"Berthiaume Institute for Precision Health\",\"cancercure\",\"Nanomedicine\",\"NotreDameResearch\",\"PATENT\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/?p=2051\",\"url\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/?p=2051\",\"name\":\"It's Official: U.S. Patent No. 12,576,160 Issued for Our Bispecific Bridge Nanoparticle Technology - Nallathamby Laboratory\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/#website\"},\"datePublished\":\"2026-03-17T17:23:00+00:00\",\"dateModified\":\"2026-05-08T05:26:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/#\\\/schema\\\/person\\\/3bec2d9fbd957b23abd53a0a5445b4f0\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/?p=2051#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/?p=2051\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/?p=2051#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"It’s Official: U.S. Patent No. 12,576,160 Issued for Our Bispecific Bridge Nanoparticle Technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/#website\",\"url\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/\",\"name\":\"Modular Nanotechnologies and Nanomaterials\",\"description\":\"Modular and scalable nanotechnology for imaging, sensing and therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/#\\\/schema\\\/person\\\/3bec2d9fbd957b23abd53a0a5445b4f0\",\"name\":\"Prakash\",\"url\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/?author=2672\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"It's Official: U.S. Patent No. 12,576,160 Issued for Our Bispecific Bridge Nanoparticle Technology - Nallathamby Laboratory","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/sites.nd.edu\/pdnano\/?p=2051","og_locale":"en_US","og_type":"article","og_title":"It's Official: U.S. Patent No. 12,576,160 Issued for Our Bispecific Bridge Nanoparticle Technology - Nallathamby Laboratory","og_description":"I am delighted to share that on March 17, 2026, the United States Patent and Trademark Office officially issued U.S. Patent No. 12,576,160 for our technology, “Bispecific bridge nanoparticles for efficient targeting of cancer cells using immunotherapy (universal CAR-T cells) or chemotherapeutic” (Notre Dame docket P21-043-US01). This is the same invention that received its Notice … Continue reading »","og_url":"https:\/\/sites.nd.edu\/pdnano\/?p=2051","og_site_name":"Nallathamby Laboratory","article_publisher":"https:\/\/www.facebook.com\/prakashdn","article_published_time":"2026-03-17T17:23:00+00:00","article_modified_time":"2026-05-08T05:26:36+00:00","author":"Prakash","twitter_card":"summary_large_image","twitter_creator":"@prakashdn","twitter_site":"@prakashdn","twitter_misc":{"Written by":"Prakash","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/sites.nd.edu\/pdnano\/?p=2051#article","isPartOf":{"@id":"https:\/\/sites.nd.edu\/pdnano\/?p=2051"},"author":{"name":"Prakash","@id":"https:\/\/sites.nd.edu\/pdnano\/#\/schema\/person\/3bec2d9fbd957b23abd53a0a5445b4f0"},"headline":"It’s Official: U.S. Patent No. 12,576,160 Issued for Our Bispecific Bridge Nanoparticle Technology","datePublished":"2026-03-17T17:23:00+00:00","dateModified":"2026-05-08T05:26:36+00:00","mainEntityOfPage":{"@id":"https:\/\/sites.nd.edu\/pdnano\/?p=2051"},"wordCount":310,"keywords":["#nallathambylab","Berthiaume Institute for Precision Health","cancercure","Nanomedicine","NotreDameResearch","PATENT"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/sites.nd.edu\/pdnano\/?p=2051","url":"https:\/\/sites.nd.edu\/pdnano\/?p=2051","name":"It's Official: U.S. Patent No. 12,576,160 Issued for Our Bispecific Bridge Nanoparticle Technology - Nallathamby Laboratory","isPartOf":{"@id":"https:\/\/sites.nd.edu\/pdnano\/#website"},"datePublished":"2026-03-17T17:23:00+00:00","dateModified":"2026-05-08T05:26:36+00:00","author":{"@id":"https:\/\/sites.nd.edu\/pdnano\/#\/schema\/person\/3bec2d9fbd957b23abd53a0a5445b4f0"},"breadcrumb":{"@id":"https:\/\/sites.nd.edu\/pdnano\/?p=2051#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/sites.nd.edu\/pdnano\/?p=2051"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/sites.nd.edu\/pdnano\/?p=2051#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/sites.nd.edu\/pdnano\/"},{"@type":"ListItem","position":2,"name":"It’s Official: U.S. Patent No. 12,576,160 Issued for Our Bispecific Bridge Nanoparticle Technology"}]},{"@type":"WebSite","@id":"https:\/\/sites.nd.edu\/pdnano\/#website","url":"https:\/\/sites.nd.edu\/pdnano\/","name":"Modular Nanotechnologies and Nanomaterials","description":"Modular and scalable nanotechnology for imaging, sensing and therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/sites.nd.edu\/pdnano\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/sites.nd.edu\/pdnano\/#\/schema\/person\/3bec2d9fbd957b23abd53a0a5445b4f0","name":"Prakash","url":"https:\/\/sites.nd.edu\/pdnano\/?author=2672"}]}},"_links":{"self":[{"href":"https:\/\/sites.nd.edu\/pdnano\/index.php?rest_route=\/wp\/v2\/posts\/2051","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sites.nd.edu\/pdnano\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sites.nd.edu\/pdnano\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sites.nd.edu\/pdnano\/index.php?rest_route=\/wp\/v2\/users\/2672"}],"replies":[{"embeddable":true,"href":"https:\/\/sites.nd.edu\/pdnano\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2051"}],"version-history":[{"count":1,"href":"https:\/\/sites.nd.edu\/pdnano\/index.php?rest_route=\/wp\/v2\/posts\/2051\/revisions"}],"predecessor-version":[{"id":2052,"href":"https:\/\/sites.nd.edu\/pdnano\/index.php?rest_route=\/wp\/v2\/posts\/2051\/revisions\/2052"}],"wp:attachment":[{"href":"https:\/\/sites.nd.edu\/pdnano\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2051"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sites.nd.edu\/pdnano\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2051"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sites.nd.edu\/pdnano\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2051"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}